Kaiyang Zhang

Kaiyang Zhang

Auto-generated profile, based on publicly available information

Kaiyang Zhang

Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2022 in Science Advances
Verified
Journal Article
Open access
KZKaiyang Zhang
Kaiyang Zhang
EEErdogan Pekcan Erkan
Erdogan Pekcan Erkan
SJSanaz Jamalzadeh
Sanaz Jamalzadeh
JDJun Dai
Jun Dai
NANoora Andersson
Noora Andersson
AVAnna Vähärautio
Anna Vähärautio
Chemotherapy resistance is a critical contributor to cancer mortality and thus an urgent unmet challenge in oncology. To characterize chemotherapy resistance processes in high-grade serous ovarian cancer, we prospectively collected tissue samples before and after chemotherapy and analyzed their transcriptomic profiles at a single-cell resolution. After removing patient-specific signals by a novel analysis approach, PRIMUS, we found a consistent increase in stress-associated cell state during chemotherapy, which was validated by RNA in situ hybridization and bulk RNA sequencing. The stress-associated state exists before chemotherapy, is subclonally enriched during the treatment, and associates with poor progression-free survival. Co-occurrence with an inflammatory cancer–associated fibroblast subtype in tumors implies that chemotherapy is associated with stress response in both cancer cells and stroma, driving a paracrine feed-forward loop. In summary, we have found a resistant state that integrates stromal signaling and subclonal evolution and offers targets to overcome chemotherapy resistance.

23 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
EPElina A. Pietilä
Elina A. Pietilä
JGJordi Gonzalez-Molina
Jordi Gonzalez-Molina
LMLidia Moyano-Galceran
Lidia Moyano-Galceran
SJSanaz Jamalzadeh
Sanaz Jamalzadeh
KZKaiyang Zhang
Kaiyang Zhang
KLKaisa Lehti
Kaisa Lehti
Due to its dynamic nature, the evolution of cancer cell-extracellular matrix (ECM) crosstalk, critically affecting metastasis and treatment resistance, remains elusive. Our results show that platinum-chemotherapy itself enhances resistance by progressively changing the cancer cell-intrinsic adhesion signaling and cell-surrounding ECM. Examining ovarian high-grade serous carcinoma (HGSC) transcriptome and histology, we describe the fibrotic ECM heterogeneity at primary tumors and distinct metastatic sites, prior and after chemotherapy. Using cell models from systematic ECM screen to collagen-based 2D and 3D cultures, we demonstrate that both specific ECM substrates and stiffness increase resistance to platinum-mediated, apoptosis-inducing DNA damage via FAK and β1 integrin-pMLC-YAP signaling. Among such substrates around metastatic HGSCs, COL6 was upregulated by chemotherapy and enhanced the resistance of relapse, but not treatment-naïve, HGSC organoids. These results identify matrix adhesion as an adaptive response, driving HGSC aggressiveness via co-evolving ECM composition and sensing, suggesting stromal and tumor strategies for ECM pathway targeting.

24 August 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
AHAriel A. Hippen
Ariel A. Hippen
MFMatias M. Falco
Matias M. Falco
LWLukas M. Weber
Lukas M. Weber
EEErdogan Pekcan Erkan
Erdogan Pekcan Erkan
KZKaiyang Zhang
Kaiyang Zhang
SHStephanie C. Hicks
Stephanie C. Hicks
Single-cell RNA-sequencing (scRNA-seq) has made it possible to profile gene expression in tissues at high resolution. An important preprocessing step prior to performing downstream analyses is to identify and remove cells with poor or degraded sample quality using quality control (QC) metrics. Two widely used QC metrics to identify a ‘low-quality’ cell are (i) if the cell includes a high proportion of reads that map to mitochondrial DNA (mtDNA) encoded genes and (ii) if a small number of genes are detected. Current best practices use these QC metrics independently with either arbitrary, uniform thresholds (e.g. 5%) or biological context-dependent (e.g. species) thresholds, and fail to jointly model these metrics in a data-driven manner. Current practices are often overly stringent and especially untenable on certain types of tissues, such as archived tumor tissues, or tissues associated with mitochondrial function, such as kidney tissue [1]. We propose a data-driven QC metric (miQC) that jointly models both the proportion of reads mapping to mtDNA genes and the number of detected genes with mixture models in a probabilistic framework to predict the low-quality cells in a given dataset. We demonstrate how our QC metric easily adapts to different types of single-cell datasets to remove low-quality cells while preserving high-quality cells that can be used for downstream analyses. Our software package is available athttps://bioconductor.org/packages/miQC.

29 September 2020 in Cell Stem Cell
Verified
Journal Article
Closed access
ARAlfredo Rodríguez
Alfredo Rodríguez
KZKaiyang Zhang
Kaiyang Zhang
AFAnniina Färkkilä
Anniina Färkkilä
JFJessica Filiatrault
Jessica Filiatrault
CYChunyu Yang
Chunyu Yang
ADAlan D. D’ANdrea
Alan D. D’ANdrea

23 July 2021 in Oncogene
Verified
Journal Article
Open access
PDF file
BSBiswajyoti Sahu
Biswajyoti Sahu
PPPäivi Pihlajamaa
Päivi Pihlajamaa
KZKaiyang Zhang
Kaiyang Zhang
KPKimmo Palin
Kimmo Palin
SASaija Ahonen
Saija Ahonen
JTJussi Taipale
Jussi Taipale
Cancer is the most complex genetic disease known, with mutations implicated in more than 250 genes. However, it is still elusive which specific mutations found in human patients lead to tumorigenesis. Here we show that a combination of oncogenes that is characteristic of liver cancer (CTNNB1, TERT, MYC) induces senescence in human fibroblasts and primary hepatocytes. However, reprogramming fibroblasts to a liver progenitor fate, induced hepatocytes (iHeps), makes them sensitive to transformation by the same oncogenes. The transformed iHeps are highly proliferative, tumorigenic in nude mice, and bear gene expression signatures of liver cancer. These results show that tumorigenesis is triggered by a combination of three elements: the set of driver mutations, the cellular lineage, and the state of differentiation of the cells along the lineage. Our results provide direct support for the role of cell identity as a key determinant in transformation and establish a paradigm for studying the dynamic role of oncogenic drivers in human tumorigenesis.

3 July 2023 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
EPEmilia Piki
Emilia Piki
ADAlice Dini
Alice Dini
JRJuuli Raivola
Juuli Raivola
KSKari Salokas
Kari Salokas
KZKaiyang Zhang
Kaiyang Zhang
DUDaniela Ungureanu
Daniela Ungureanu
Wnt pathway dysregulation through genetic and non-genetic alterations occurs in multiple cancers, including ovarian cancer (OC). The aberrant expression of the non-canonical Wnt signaling receptor ROR1 is thought to contribute to OC progression and drug resistance. However, the key molecular events mediated by ROR1 that are involved in OC tumorigenesis are not fully understood. Here, we show that ROR1 expression is enhanced by neoadjuvant chemotherapy, and Wnt5a binding to ROR1 can induce oncogenic signaling via AKT/ERK/STAT3 activation in OC cells. Proteomics analysis of isogenic ROR1-knockdown OC cells identified STAT3 as a downstream effector of ROR1 signaling. Transcriptomics analysis of clinical samples (n = 125) revealed that ROR1 and STAT3 are expressed at higher levels in stromal cells than in epithelial cancer cells of OC tumors, and these findings were corroborated by multiplex immunohistochemistry (mIHC) analysis of an independent OC cohort (n = 11). Our results show that ROR1 and its downstream STAT3 are co-expressed in epithelial as well as stromal cells of OC tumors, including cancer-associated fibroblasts or CAFs. Our data provides the framework to expand the clinical utility of ROR1 as a therapeutic target to overcome OC progression.